Cargando…

Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey

OBJECTIVE: This retrospective multicenter study, centrally conducted and supported by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) patients. Surgical timing, adequacy of the treatment, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Aydoğan, Berna İmge, Yüksel, Bağdagül, Tuna, Mazhar Müslüm, Navdar Başaran, Mehtap, Akkurt Kocaeli, Ayşen, Ertörer, Melek Eda, Aydın, Kadriye, Güldiken, Sibel, Şimşek, Yasin, Cihan Karaca, Züleyha, Yılmaz, Merve, Aktürk, Müjde, Anaforoğlu, İnan, Kebapçı, Nur, Duran, Cevdet, Taşlıpınar, Abdullah, Kulaksızoğlu, Mustafa, Gürsoy, Alptekin, Dağdelen, Selçuk, Erdoğan, Murat Faik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805043/
https://www.ncbi.nlm.nih.gov/pubmed/26758973
http://dx.doi.org/10.4274/jcrpe.2219
_version_ 1782423080314863616
author Aydoğan, Berna İmge
Yüksel, Bağdagül
Tuna, Mazhar Müslüm
Navdar Başaran, Mehtap
Akkurt Kocaeli, Ayşen
Ertörer, Melek Eda
Aydın, Kadriye
Güldiken, Sibel
Şimşek, Yasin
Cihan Karaca, Züleyha
Yılmaz, Merve
Aktürk, Müjde
Anaforoğlu, İnan
Kebapçı, Nur
Duran, Cevdet
Taşlıpınar, Abdullah
Kulaksızoğlu, Mustafa
Gürsoy, Alptekin
Dağdelen, Selçuk
Erdoğan, Murat Faik
author_facet Aydoğan, Berna İmge
Yüksel, Bağdagül
Tuna, Mazhar Müslüm
Navdar Başaran, Mehtap
Akkurt Kocaeli, Ayşen
Ertörer, Melek Eda
Aydın, Kadriye
Güldiken, Sibel
Şimşek, Yasin
Cihan Karaca, Züleyha
Yılmaz, Merve
Aktürk, Müjde
Anaforoğlu, İnan
Kebapçı, Nur
Duran, Cevdet
Taşlıpınar, Abdullah
Kulaksızoğlu, Mustafa
Gürsoy, Alptekin
Dağdelen, Selçuk
Erdoğan, Murat Faik
author_sort Aydoğan, Berna İmge
collection PubMed
description OBJECTIVE: This retrospective multicenter study, centrally conducted and supported by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) patients. Surgical timing, adequacy of the treatment, and frequency of prophylactic thyroidectomy (PTx) in mutation carriers were also assessed. METHODS: Genetic testing for MTC and pheochromocytoma was conducted between July 2008 and January 2012 in 512 patients. Application forms and RET mutation analyses of these patients whose blood samples were sent from various centers around Turkey were assessed retrospectively. An evaluation form was sent to the physicians of the eligible 319 patients who had confirmed sporadic MTC, familial MTC (FMTC), multiple endocrine neoplasia type 2 (MEN2), or who were mutation carriers. Physicians were asked to give information about the surgical history, latest calcitonin levels, morbidity, mortality, genetic screening, and PTx among family members. Twenty-five centers responded by filling in the forms of 192 patients. RESULTS: Among the 319 patients, RET mutation was detected in 71 (22.3%). Cys634Arg mutation was the most prevalent mutation (43.7%), followed by Val804Met in 18 patients (25.4%), and Cys634Tyr in 6 patients (8.5%). Among 192 MTC patients, the diagnosis was sporadic MTC in 146 (76.4%), FMTC in 14 (7.3%), MEN2A in 15 patients (7.9%), and MEN2B in one patient. The number of mutation carriers among 154 apparently sporadic MTC patients was 8 (5.2%). Ten patients were submitted to PTx out of twenty-four mutation carriers at a mean age of 35±19 years. CONCLUSION: Turkish people have a similar RET proto-oncogene mutation distribution when compared to other Mediterranean countries. Despite free RET gene testing, the number of the PTx in Turkey is limited and relatively late in the life span of the carriers. This is mainly due to patient and family incompliance and incomplete family counselling.
format Online
Article
Text
id pubmed-4805043
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-48050432016-04-06 Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey Aydoğan, Berna İmge Yüksel, Bağdagül Tuna, Mazhar Müslüm Navdar Başaran, Mehtap Akkurt Kocaeli, Ayşen Ertörer, Melek Eda Aydın, Kadriye Güldiken, Sibel Şimşek, Yasin Cihan Karaca, Züleyha Yılmaz, Merve Aktürk, Müjde Anaforoğlu, İnan Kebapçı, Nur Duran, Cevdet Taşlıpınar, Abdullah Kulaksızoğlu, Mustafa Gürsoy, Alptekin Dağdelen, Selçuk Erdoğan, Murat Faik J Clin Res Pediatr Endocrinol Original Article OBJECTIVE: This retrospective multicenter study, centrally conducted and supported by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) patients. Surgical timing, adequacy of the treatment, and frequency of prophylactic thyroidectomy (PTx) in mutation carriers were also assessed. METHODS: Genetic testing for MTC and pheochromocytoma was conducted between July 2008 and January 2012 in 512 patients. Application forms and RET mutation analyses of these patients whose blood samples were sent from various centers around Turkey were assessed retrospectively. An evaluation form was sent to the physicians of the eligible 319 patients who had confirmed sporadic MTC, familial MTC (FMTC), multiple endocrine neoplasia type 2 (MEN2), or who were mutation carriers. Physicians were asked to give information about the surgical history, latest calcitonin levels, morbidity, mortality, genetic screening, and PTx among family members. Twenty-five centers responded by filling in the forms of 192 patients. RESULTS: Among the 319 patients, RET mutation was detected in 71 (22.3%). Cys634Arg mutation was the most prevalent mutation (43.7%), followed by Val804Met in 18 patients (25.4%), and Cys634Tyr in 6 patients (8.5%). Among 192 MTC patients, the diagnosis was sporadic MTC in 146 (76.4%), FMTC in 14 (7.3%), MEN2A in 15 patients (7.9%), and MEN2B in one patient. The number of mutation carriers among 154 apparently sporadic MTC patients was 8 (5.2%). Ten patients were submitted to PTx out of twenty-four mutation carriers at a mean age of 35±19 years. CONCLUSION: Turkish people have a similar RET proto-oncogene mutation distribution when compared to other Mediterranean countries. Despite free RET gene testing, the number of the PTx in Turkey is limited and relatively late in the life span of the carriers. This is mainly due to patient and family incompliance and incomplete family counselling. Galenos Publishing 2016-03 2016-03-01 /pmc/articles/PMC4805043/ /pubmed/26758973 http://dx.doi.org/10.4274/jcrpe.2219 Text en © Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Aydoğan, Berna İmge
Yüksel, Bağdagül
Tuna, Mazhar Müslüm
Navdar Başaran, Mehtap
Akkurt Kocaeli, Ayşen
Ertörer, Melek Eda
Aydın, Kadriye
Güldiken, Sibel
Şimşek, Yasin
Cihan Karaca, Züleyha
Yılmaz, Merve
Aktürk, Müjde
Anaforoğlu, İnan
Kebapçı, Nur
Duran, Cevdet
Taşlıpınar, Abdullah
Kulaksızoğlu, Mustafa
Gürsoy, Alptekin
Dağdelen, Selçuk
Erdoğan, Murat Faik
Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
title Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
title_full Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
title_fullStr Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
title_full_unstemmed Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
title_short Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
title_sort distribution of ret mutations and evaluation of treatment approaches in hereditary medullary thyroid carcinoma in turkey
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805043/
https://www.ncbi.nlm.nih.gov/pubmed/26758973
http://dx.doi.org/10.4274/jcrpe.2219
work_keys_str_mv AT aydoganbernaimge distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT yukselbagdagul distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT tunamazharmuslum distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT navdarbasaranmehtap distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT akkurtkocaeliaysen distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT ertorermelekeda distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT aydınkadriye distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT guldikensibel distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT simsekyasin distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT cihankaracazuleyha distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT yılmazmerve distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT akturkmujde distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT anaforogluinan distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT kebapcınur distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT durancevdet distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT taslıpınarabdullah distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT kulaksızoglumustafa distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT gursoyalptekin distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT dagdelenselcuk distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey
AT erdoganmuratfaik distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey